a study on SDI-DLB concerning to diagnose DLB and assess benefit for Donepezil : Study 1

a study on SDI-DLB concerning to diagnose DLB and assess benefit for Donepezil : Study 1 - SDI-DLB: diagnose DLB and assess benefit for Donepezil(Study 1)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000018889

Enrollment

150

Registered

2015-09-03

Start date

2015-09-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

DLB

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)met criteria of probable DLB in CDLB 3rd 2)gave informed consent 3)60 years old or more of age 4)outpatients or home visited patients 5)have carer spend time with 72 hours or more every week

Exclusion criteria

Exclusion criteria: 1)dozed antidementia drugs except Donepezil within 12 weeks before informed consent 2)bed ridden 3)with severe impairment of visual acuity, auditory sensor and/or communication 4)with neurological degenerative disease except for DLBV criteria, schizophrenia, bipolar disorder and major depression 5)with delirium due to abuse of alcohol, drugs, metabolic toxicity and inflammation

Design outcomes

Primary

Measure	Time frame
The correlation between SDI-DLB scores and scores of MMSE, PSMS and EQ-5D.	—

Secondary

Measure	Time frame
The correlation between SDI-DLB scores and scores of MMSE, PSMS and EQ-5D.	—

Countries

Japan

Contacts

Public ContactAsako Yasuda

Promedico Co., Ltd. Projects Promotion Department

asako.yasuda@promedico.co.jp03-5332-3265

Outcome results